Levomilnacipran Extended Release: First Global Approval-Reference-Cited by-同舟云学术

Levomilnacipran Extended Release: First Global Approval

Published:2013-09 Issue:14 Volume:73 Page:1639-1645
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hair Philip,Cameron Fiona,Garnock-Jones Karly P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-013-0116-1.pdf

Reference21 articles.

1. Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the global burden of disease study 2010. PLoS ONE. 2013;8(7):e69637.

2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. 2010. http://www.guideline.gov/content.aspx?id=24158 . Accessed 14 Aug 2013.

3. US FDA. Letter of New Drug Application approval for levomilnacipran extended-release capsules [NDA 204168]. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204168Orig1s000ltr.pdf . Accessed 16 Aug 2013.

4. Forest Laboratories Inc., Pierre Fabre Laboratories. Forest Laboratories Submits New Drug Application for Levomilnacipran for the Treatment of Major Depressive Disorder [media release]. Sep 27 2012. http://www.frx.com .

5. Forest Laboratories Inc. FETZIMA™ (levomilnacipran extended-release capsules) US prescribing information. 2013. http://www.frx.com/pi/Fetzima_pi.pdf . Accessed 14 Aug 2013.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design;Bioorganic & Medicinal Chemistry Letters;2024-03

2. Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials;Experimental and Therapeutic Medicine;2023-09-20

3. Levomilnacipran ameliorates lipopolysaccharide-induced depression-like behaviors and suppressed the TLR4/Ras signaling pathway;International Immunopharmacology;2023-09

4. Antidepressant Drugs: Mechanisms of Action and Side Effects;Encyclopedia of Behavioral Neuroscience, 2nd edition;2022

5. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review;Current Neuropharmacology;2016-02-15